Hackensack Meridian Health has unveiled a cancer risk and early detection program in partnership with CancerIQ, utilizing advanced technology to streamline cancer risk assessments and personalize care plans. The program includes a CancerIQ tool that identifies individuals with higher cancer risk, offering personalized prevention and detection strategies. By leveraging molecular cancer screening techniques like liquid biopsies, the program aims to detect cancer at its earliest stages. This initiative is part of HMH’s Hennessy Institute for Cancer Prevention and Applied Molecular Medicine, with plans to expand to other locations. The program aligns with the global trend of preventing cancer through improved access to genetic testing and personalized care plans. Other companies in the precision oncology space, like GE HealthCare and BAMF Health, are also working on innovative cancer detection and treatment methods.
Source link
Hackensack Meridian Health, CancerIQ partner on cancer risk, early detection program
